Vertex Pharma, US92532F1003

Vertex Pharma stock gains 3 percent ahead of the open

Published on 09/23/2026 at 02:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 22, 2026, Vertex Pharma stock had gained 3 percent after positive kidney-disease trial results, while the Nasdaq Composite rose 0.5 percent to 27,244.28.

Wissenschaftler pipettiert Proben in modernem Biotech-Labor mit Automatisierungsgeräten
Vertex Pharma US92532F1003 zeigt einen Forscher im modernen Labor mit Pipette an sterilem Edelstahltisch, Illustration mit AI erstellt.

Vertex Pharma stock closed at USD 524.05 on the Nasdaq on September 22, 2026, up 3 percent. The Nasdaq Composite rose 0.5 percent to 27,244.28 in the same session, giving Vertex a gain of 2.5 percentage points over the reference index.

September 22, 2026 in numbers

Vertex Pharmaceuticals Incorporated (ISIN US92532F1003, Nasdaq: VRTX) traded at USD 524.05 after the company announced positive AMPLIFIED study results for inaxaplin. As Business Wire reported on September 22, 2026, the study showed a 42.7 percent reduction in a kidney-disease proteinuria measure in one patient group.

The company also completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim data expected in early 2027. Vertex gained 3 percent while the Nasdaq Composite added 0.5 percent on September 22, 2026.

Today after the trial update

The AMPLIFIED results remain the key company-specific development for Vertex on September 23, 2026. As Investing.com reported on September 22, 2026, BMO Capital reiterated an Outperform rating and a USD 600 price target after the trial data.

Disclaimer...

en | US92532F1003 | VERTEX PHARMA | boerse | 70160888 | bgmi